ADAR1 Capital Management LLC Grows Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

ADAR1 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 114.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 647,960 shares of the biotechnology company’s stock after buying an additional 345,748 shares during the quarter. ADAR1 Capital Management LLC owned 1.09% of Aldeyra Therapeutics worth $3,233,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Aldeyra Therapeutics during the fourth quarter worth about $3,628,000. Jacobs Levy Equity Management Inc. grew its position in shares of Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after buying an additional 295,864 shares during the last quarter. Kennondale Capital Management LLC acquired a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth about $755,000. Trexquant Investment LP grew its position in shares of Aldeyra Therapeutics by 895.5% during the fourth quarter. Trexquant Investment LP now owns 114,480 shares of the biotechnology company’s stock worth $571,000 after acquiring an additional 102,980 shares during the last quarter. Finally, Barclays PLC boosted its stake in Aldeyra Therapeutics by 280.1% during the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 48,313 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a report on Friday.

Aldeyra Therapeutics Stock Up 33.1 %

Shares of Aldeyra Therapeutics stock opened at $1.89 on Monday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics, Inc has a 52-week low of $1.14 and a 52-week high of $7.20. The company’s 50-day simple moving average is $6.00 and its 200-day simple moving average is $5.44.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.30). Analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.